Click it and Unblock the Notifications
Latest Updates
-
H1N1 Cases Cross 1,300 In Delhi: Is Your Parent Or Child In The H1N1 Danger Zone? -
Independence Day 2026: Flag Code Rules Every Indian Must Know Before Hoisting the Tricolour -
Jharkhand Student Protest: Who Is Devendra Nath Mahto, The Face Of The Recruitment Exam Agitation? -
Acidity Is a Symptom, Not a Diagnosis: Why Self-Medicating Can Backfire -
Tricolour At The Desk: Independence Day 2026 Office Outfit Ideas That Work -
World Biofuel Day 2026: Significance, Benefits And India’s Growing Push With Sampoorn Gobardhan Scheme -
Sawan Shivratri 2026: Jalabhishek Timings, Rituals And Significance Explained -
Second Shravan Somwar 2026: Why August 10 Is Extra Special For Lord Shiva Devotees This Year -
Soma Pradosh Vrat 2026: Significance, Puja Vidhi, Fasting Rules And Why Shravan Makes It Special -
Monsoon Foot Care: Why Wet Feet Can Lead To Fungal Infections And Skin Damage
biocon JV-Abu Dhabi's Neopharma
New Delhi, Jan 5 (UNI) biocon Ltd today announced a joint venture agreement with Abu Dhabi-based pharmaceutical company Neopharma to manufacture and market bio-pharmaceuticals for the GCC countries.
''The Gulf Cooperation Council (GCC) region is an important market for biocon and the joint venture with Neopharma is an important milestone for biocon's global foray. Neopharma has established a world-class manufacturing facility for finished formulations which was inaugurated by President A P J Abdul Kalam in 2003,'' company Chairman and Managing Director Dr Kiran Mazumdar-Shaw said.
The JV will leverage the leadership position that Neopharma commands in the region under the leadership of Dr B R Shetty and expand Neopharma's existing portfolio with a range of the company's generic and novel therapeutics that encompass diabetes, oncology, auto-immune and immunosuppressive drugs, biocon said.
Continue with Google